понедельник, 27 февраля 2017 г.

Veracyte: An Ideal Medium-Term Runner With Long-Term Upside

Veracyte: An Ideal Medium-Term Runner With Long-Term Upside


Slew of recent good news includes Medicare coverage of Percepta, agreement with Quest Diagnostics granting access to Afirma GEC test, and increased coverage for the latter with insurers. A year's worth of cash on the books, raised full year guidance by management, and convincing clinical evidence to be published for Envisia Genomic Classifier add to bull case.



from Biotech News